We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Ergomed Plc | LSE:ERGO | London | Ordinary Share | GB00BN7ZCY67 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 1,346.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
TIDMERGO
RNS Number : 8031U
Ergomed plc
16 July 2018
PRESS RELEASE
16 July 2018
Notification re Change of Auditors
Ergomed plc ("Ergomed" or the "Company")
At the Company's Annual General Meeting held on 12 June 2018, a resolution to appoint KPMG as Ergomed's auditors was proposed and approved by shareholders.
Ergomed now announces that on 13 July 2018 it wrote to shareholders explaining that, as planned, Deloitte LLP had resigned as auditor and KPMG had been appointed as the Company's new auditor. And as required by the Companies Act the Company also sent to shareholders a statement of Deloitte's reasons for their ceasing to hold office (namely that the directors of Ergomed have decided to appoint another firm as auditors).
This announcement is being made pursuant to the requirements of AIM Rule 20.
Enquiries:
Hot Features
Premium
Ergomed plc Tel: +44 (0) 1483 503
205
Stuart Jackson (Chief Financial Officer)
Numis Securities Limited Tel: +44 (0) 20 7260
1000
Michael Meade / Freddie Barnfield (Nominated
Adviser)
James Black (Joint Broker)
N+1 Singer Tel: +44 (0) 20 7496
3000
Aubrey Powell (Joint Broker)
Consilium Strategic Communications Tel: +44 (0) 20 3709
- for UK enquiries 5700
Chris Gardner / Mary-Jane Elliott ergomed@consilium-comms.com
Ivar Milligan / Olivia Manser
MC Services - for Continental European Tel: +49 211 5292 5222
enquiries
Anne Hennecke
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services offering encompasses a complete suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, in addition to a full range of high quality contract research and trial management services (CRO). Leveraging its CRO expertise, Ergomed also has a drug development portfolio of co-development partnerships and wholly-owned programmes. For further information, visit: http://ergomedplc.com.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
MSCEAKXKFAXPEFF
(END) Dow Jones Newswires
July 16, 2018 12:31 ET (16:31 GMT)
1 Year Ergomed Chart |
1 Month Ergomed Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
